AI in Healthcare Startups: Investor Insights
- Venture capitalists are increasingly prioritizing artificial intelligence (AI) and automation when considering investments in health tech, medtech, and biopharma.
- Gurdane Bhutani, managing partner at MBX Capital, emphasized the firm's focus on companies addressing the root causes of illness.
- Morgan Cheatham, a partner at Breyer Capital, noted that his firm, founded by early Facebook investor Jim Breyer, concentrates on early-stage startups at the intersection of healthcare, life...
Venture capitalists are actively integrating artificial intelligence (AI) into their health tech investment strategies. Hear from experts on how AI is reshaping funding decisions for startups in medtech, health tech, and biopharma. Learn how specialized AI models are reducing risks in drug progress, and why in vivo data is crucial for securing financing. This report,sponsored by Mercury,also spotlights the growing role family offices play in fueling thes ventures. Discover the critical impact of AI on equity valuations and corporate strategies within the healthcare landscape. News Directory 3 provides insights on how to stay ahead in this dynamic market. Discover what’s next in AI-driven healthcare investment.
Venture Capitalists Eye AI’s Growing role in Health Tech Investments
Updated June 15, 2025
Venture capitalists are increasingly prioritizing artificial intelligence (AI) and automation when considering investments in health tech, medtech, and biopharma. During a recent webinar sponsored by Mercury, a business banking provider, experts discussed how AI is reshaping the landscape and influencing funding decisions for startups. The discussion highlighted the importance of alternative funding sources beyond government grants for emerging companies.
Gurdane Bhutani, managing partner at MBX Capital, emphasized the firm’s focus on companies addressing the root causes of illness. MBX Capital invests in upstream drivers of health outcomes, health tech leveraging AI for improved care quality, and biotech research tools. Bhutani’s background is in epidemiology and toxicology.
Morgan Cheatham, a partner at Breyer Capital, noted that his firm, founded by early Facebook investor Jim Breyer, concentrates on early-stage startups at the intersection of healthcare, life sciences, and technology. AI and precision medicine are key investment principles for Breyer Capital. Cheatham is also a trained physician in genetics.
Ben Kromnick, who leads healthcare and life sciences at Mercury, brings experience building big data and machine learning platforms for major healthcare and insurance companies. He leverages this background to support Mercury’s clients in the healthcare sector.
The webinar panelists underscored the direct impact of specialized AI applications on equity valuations and corporate development strategies within the healthcare industry. The role of AI in healthcare startup investment and collaboration strategies was a dominant theme.
“If you’re a company that’s focused on the autoimmune space and you’re developing a modulating agent,you ought to be concerned with immunogenicity as a key risk to your program,” Cheatham said.
Cheatham suggested that companies should develop specialized models targeting specific risks, such as immunogenicity reduction, rather then broadly applying AI across multiple areas. This targeted approach can increase the probability of success.
Cheatham also highlighted the significance of in vivo validation data in driving business development efforts with biopharma companies and securing subsequent financing rounds for startups.This data is critical for achieving key milestones.
What’s next
the panelists also touched on grant funding strategies,capital valuation,lean startup methodologies,using AI to reduce risk,and the increasing role of family offices in providing capital to health tech ventures. The increasing role of family offices in providing capital to health tech ventures is expected to continue.